Moreover, combination therapies of anti-PD-1/PD-L1 with anti-angiogenic agents (e.g., bevacizumab) have shown superior efficacy compared to traditional treatments like sorafenib, representing a major advancement in therapeutic strategies for HCC [30]. The gene discussed is CD274; the disease is hepatocellular carcinoma.